The anticancer immune response: indispensable for therapeutic success?

被引：494
作者：
Zitvogel, Laurence [1 ,3 ,4 ]
Apetoh, Lionel [1 ,4 ]
Ghiringhelli, Francois [1 ,3 ]
Andre, Fabrice
Tesniere, Antoine [2 ,4 ]
Kroemer, Guido [2 ,4 ]
机构：
[1] Inst Gustave Roussy, INSERM, U805, F-94805 Villejuif, France
[2] INSERM, U848, Villejuif, France
[3] CIC BT507, Villejuif, France
[4] Univ Paris 11, Fac Med, Le Kremlin Bicetre, France
来源：
JOURNAL OF CLINICAL INVESTIGATION | 2008年 / 118卷 / 06期
关键词：
D O I：
10.1172/JCI35180
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Although the impact of tumor immunology on the clinical management of most cancers is still negligible, there is increasing evidence that anticancer immune responses may contribute to the control of cancer after conventional chemotherapy. Thus, radiotherapy and some chemotherapeutic agents, in particular anthracyclines, can induce specific immune responses that result either in immunogenic cancer cell death or in immunostimulatory side effects. This anticancer immune I response then helps to eliminate residual cancer cells (those that fail to be killed by chemotherapy) or maintains micrometastases in a stage of dormancy. Based on these premises, in this Review we address the question, How may it be possible to ameliorate conventional therapies by stimulating the anticancer immune response? Moreover, we discuss the rationale of clinical trials to evaluate and eventually increase the contribution of antitumor immune responses to the therapeutic management of neoplasia.
引用
收藏
页码：1991 / 2001
页数：11
相关论文
共 129 条
  • [1] Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer
    Antonia, SJ
    Mirza, N
    Fricke, I
    Chiappori, A
    Thompson, P
    Williams, N
    Bepler, G
    Simon, G
    Janssen, W
    Lee, JH
    Menander, K
    Chada, S
    Gabrilovich, DI
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (03) : 878 - 887
  • [2] The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy
    Apetoh, Lionel
    Ghiringhelli, Francois
    Tesniere, Antoine
    Criollo, Alfredo
    Ortiz, Carla
    Lidereau, Rosette
    Mariette, Christophe
    Chaput, Nathalie
    Mira, Jean-Paul
    Delaloge, Suzette
    Andre, Fabrice
    Tursz, Thomas
    Kroemer, Guido
    Zitvogel, Laurence
    [J]. IMMUNOLOGICAL REVIEWS, 2007, 220 : 47 - 59
  • [3] Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
    Apetoh, Lionel
    Ghiringhelli, Francois
    Tesniere, Antoine
    Obeid, Michel
    Ortiz, Carla
    Criollo, Alfredo
    Mignot, Gregoire
    Maiuri, M. Chiara
    Ullrich, Evelyn
    Saulnier, Patrick
    Yang, Huan
    Amigorena, Sebastian
    Ryffel, Bernard
    Barrat, Franck J.
    Saftig, Paul
    Levi, Francis
    Lidereau, Rosette
    Nogues, Catherine
    Mira, Jean-Paul
    Chompret, Agnes
    Joulin, Virginie
    Clavel-Chapelon, Francoise
    Bourhis, Jean
    Andre, Fabrice
    Delaloge, Suzette
    Tursz, Thomas
    Kroemer, Guido
    Zitvogel, Laurence
    [J]. NATURE MEDICINE, 2007, 13 (09) : 1050 - 1059
  • [4] Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer
    Aragon-Ching, Jeanny B.
    Williams, Kirsten M.
    Gulley, James L.
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2007, 12 : 4957 - 4971
  • [5] TLR4 mutations are associated with endotoxin hyporesponsiveness in humans
    Arbour, NC
    Lorenz, E
    Schutte, BC
    Zabner, J
    Kline, JN
    Jones, M
    Frees, K
    Watt, JL
    Schwartz, DA
    [J]. NATURE GENETICS, 2000, 25 (02) : 187 - +
  • [6] A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer
    Arlen, PM
    Gulley, JL
    Parker, C
    Skarupa, L
    Pazdur, M
    Panicali, D
    Beetham, P
    Tsang, KY
    Grosenbach, DW
    Feldman, J
    Steinberg, SM
    Jones, E
    Chen, C
    Marte, J
    Schlom, J
    Dahut, W
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (04) : 1260 - 1269
  • [7] Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D Ligands by the histone deacetylase inhibitor sodium valproate
    Armeanu, S
    Bitzer, M
    Lauer, UM
    Venturelli, S
    Pathil, A
    Krusch, M
    Kaiser, S
    Jobst, K
    Smirnow, I
    Wagner, A
    Steinle, A
    Salih, HR
    [J]. CANCER RESEARCH, 2005, 65 (14) : 6321 - 6329
  • [8] ASAO T, 1992, CANCER RES, V52, P6254
  • [9] Interleukin-2/interferon-α2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma:: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
    Atzpodien, J.
    Kirchner, H.
    Rebmann, U.
    Soder, M.
    Gertenbach, U.
    Siebels, M.
    Roigas, J.
    Raschke, R.
    Salm, S.
    Schwindl, B.
    Mueller, S. C.
    Hauser, S.
    Leiber, C.
    Huland, E.
    Heinzer, H.
    Siemer, S.
    Metzner, B.
    Heynemann, H.
    Fornara, P.
    Reitz, M.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (04) : 463 - 469
  • [10] Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination
    Badovinac, VP
    Messingham, KAN
    Jabbari, A
    Haring, JS
    Harty, JT
    [J]. NATURE MEDICINE, 2005, 11 (07) : 748 - 756
12345678910